Scientific Bioprocessing

Executive Summary

Scientific Bioprocessing (SBI) is a U.S.-based biotechnology company that has pioneered the DOTS Platform, a sensor and software system that transforms standard laboratory shake flasks into 'smart bioreactors.' Founded in 2015 and headquartered in Pittsburgh, SBI enables real-time monitoring and control of critical bioprocess parameters such as dissolved oxygen and biomass, thereby accelerating process development for biologics manufacturing. The technology is adopted by both industry and academic researchers, offering improved scalability and data quality in upstream bioprocessing. By replacing traditional offline sampling with continuous, non-invasive monitoring, SBI reduces development timelines and costs, addressing a key bottleneck in biologics production. The global biologics market is expanding rapidly, driving demand for more efficient and data-rich process development tools. SBI's platform fills a critical gap by bringing advanced monitoring capabilities to the widely used shake flask format, which remains a staple in early-stage R&D. With increasing regulatory emphasis on quality by design (QbD) and process analytical technology (PAT), SBI is well-positioned to capture market share. The company's focus on upstream processing, combined with its software-driven analytics, creates a defensible competitive moat. Given its proven traction in both academic and commercial settings, SBI represents a compelling investment opportunity in the bioprocessing tools space.

Upcoming Catalysts (preview)

• Q2 2026Launch of expanded DOTS sensor suite including pH and glucose monitoring80% success
• Q4 2026Strategic partnership with a top-10 biopharma for adoption in commercial manufacturing60% success
• Q3 2026FDA acceptance of DOTS-generated data for regulatory submissions50% success